Plexus Insider Sold Shares Worth $1,220,921, According to a Recent SEC Filing-February 2024-www.financetom.com

Plexus Insider Sold Shares Worth $1,220,921, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Plexus Insider Sold Shares Worth $1,220,921, According to a Recent SEC Filing

Jun 3, 2024 12:51 AM

03:35 AM EDT, 06/03/2024 (MT Newswires) -- Todd P. Kelsey, Director, Chief Executive Officer, on May 29, 2024, sold 11,061 shares in Plexus (PLXS) for $1,220,921. Following the Form 4 filing with the SEC, Kelsey has control over a total of 102,338 shares of the company, with 102,338 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/785786/000162828024026074/xslF345X03/wk-form4_1717189136.xml

Previous page： Air Canada reports smaller adjusted loss on business travel rebound Next page： Google faces closing arguments in US market power trial

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Air Canada reports smaller adjusted loss on business travel rebound

May 2, 2024

(Reuters) - Air Canada ( ACDVF ) reported a smaller first-quarter adjusted loss on Thursday, as Canada's largest carrier benefited from a rebound in bookings for business travel. Major North American carriers are cashing in on a resurgence in big spending by corporate customers who have been largely absent from the post-pandemic travel boom. Executives at Air Canada's ( ACDVF...

Google faces closing arguments in US market power trial

May 2, 2024

WASHINGTON (Reuters) - The U.S. government will layout its antitrust case against Alphabet's Google in closing arguments on Thursday, wrapping up a trial in which the online search leader is accused of breaking the law to stay on top. The U.S. government has hammered away at Google in a trial that started Sept. 12, arguing Google is a monopolist and...

Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos

May 2, 2024

06:04 AM EDT, 05/02/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) and Astellas Pharma subsidiary Xyphos Biosciences have entered into a research partnership and license agreement to develop new cancer cell therapy platforms using the Xyphos' convertible chimeric antigen receptor technology, the companies said Wednesday. Under the terms of the deal, the companies plan to combine proprietary gene therapy...

Tech giants' market cap falls on AI doubts, high rates; Alphabet, Tesla gain

May 2, 2024

(Reuters) - The market capitalisation of top technology giants fell sharply in April, pressured by diminishing enthusiasm for artificial intelligence and a scaling back of expectations for central bank interest rate cuts. Microsoft's market value plummeted by $232.5 billion, or 7.4%, ending the month at $2.89 trillion. Meta Platforms Inc ( META ) also suffered a drop of $146.8 billion,...